| 引用本文: | 孙涛,王江蓉,陈军,尹林,贾小芳,卢洪洲,张丽军.HIV感染者中唐草片对洛匹那韦药动学的影响[J].中国现代应用药学,2016,33(9):1119-1123. |
| SUN Tao,WANG Jiangrong,CHEN Jun,YIN Lin,JIA Xiaofang,LU Hongzhou,ZHANG Lijun.Study the Pharmacokinetic Effect of Tangcao Tablet on Lopinavir in HIV-infected Patients[J].Chin J Mod Appl Pharm(中国现代应用药学),2016,33(9):1119-1123. |
|
| 摘要: |
| 目的 探讨唐草片对洛匹那韦在HIV感染者中的药动学的影响。方法 入组单纯服用含洛匹那韦的高效抗逆(反)转录病毒治疗方案的患者，达稳态后采血，然后联合服用唐草片2周后采血。采血时间点为：服用洛匹那韦前(0 h)、后0.5，1.0，2.0，3.0，4.0，6.0，8.0，10.0和12.0 h的样本，液相色谱串联质谱检测血浆中洛匹那韦浓度，并采用DAS 2.1.1软件计算药动学参数。结果 入组16例HIV感染者，单纯服用洛匹那韦组合者中的洛匹那韦AUC0-t为(100.12±57.72)mg·L-1·h-1， Cmax为(13.24±8.35)mg·L-1，Tmax为(4.16±2.39)h，T1/2为(9.62±7.57)h；同时服用唐草片后，洛匹那韦的AUC0-t为(95.55± 58.50)mg·L-1·h-1，Cmax为(12.36±7.26)mg·L-1，Tmax为(4.06±3.06)h，T1/2为(9.20±7.18)h。2组之间各参数均无显著差异。结论 唐草片对HIV感染者中洛匹那韦的药动学参数无影响。 |
| 关键词: 唐草片 艾滋病 洛匹那韦 药动学 相互作用 |
| DOI： |
| 分类号:R969.1 |
| 基金项目:“重大新药创制”国家科技重大专项(2012ZX09303013)；国家自然科学基金(81271834)；国家高技术研究发展计划(863计划)(2014AA 021403)；上海市科学技术委员会科研计划项目(15DZ2290200，13ZR1460100) |
|
| Study the Pharmacokinetic Effect of Tangcao Tablet on Lopinavir in HIV-infected Patients |
|
SUN Tao1, WANG Jiangrong2, CHEN Jun2, YIN Lin2, JIA Xiaofang2, LU Hongzhou2,3, ZHANG Lijun1
|
|
1.School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou 325035, China;2.Shanghai Public Health Clinical Center, Shanghai 201508, China;3.Huashan Hospital Affiliated to Fudan University, Shanghai 200040, China
|
| Abstract: |
| OBJECTIVE To investigate the pharmacokinetic effect of Tangcao tablet on lopinavir in HIV-infected patients. METHODS Enrolling HIV-infected patients with highly active antiretroviral therapy(HAART) including lopinavir up to steady state. Blood samples were obtained at 0, 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0 and 12.0 h, respectively after treating with lopinavir. The patients were given Tangcao tablet together with HAART thereafter for 2 weeks. Blood samples were obtained again and analyzed. The drug concentration was detected by liquid chromatography tandem mass spectrometry (LC-MS). The statistic analysis was performed by DAS2.1.1 software. RESULTS Sixteen eligible HIV-infected patients were enrolled. The AUC, Cmax, Tmax and T1/2 of lopinavir were (100.12±57.72)mg·L-1·h-1, (13.24±8.35)mg·L-1, (4.16±2.39)h, (9.62±7.57)h before taking Tangcao tablet and were (95.55±58.50)mg·L-1·h-1, (12.36±7.26)mg·L-1, (4.06±3.06)h, (9.20±7.18)h after combination with Tangcao tablet, respectively. No significant difference was found between the two groups. CONCLUSION Tangcao tablet has no impact on the pharmacokinetics parameters of lopinavir in HIV-infected patients. |
| Key words: Tang Herb HIV lopinavir pharmacokinetics drug interactions |
